Global Human Combination Vaccines Market to Grow at a CAGR of 9% Through 2021, Announces Technavio

Technavio has published a new report on the global human combination vaccines market from 2017-2021. (Graphic: Business Wire)

???pagination.previous??? ???pagination.next???

LONDON--()--The global human combination vaccines market is expected to grow at a CAGR of close to 9% during the forecast period, according to Technavio’s latest market research.

In this market research report, Technavio covers the market outlook and growth prospects of the global human combination vaccines market for 2017-2021. The market is further categorized into two types comprising of human combination inactivated vaccines and human combination live attenuated vaccines. The human combination live attenuated vaccines accounted for more than 80% of the market share in 2016.

"The global human combination vaccines market will grow at a high rate during the forecast period due to increasing cases of infectious diseases in developed and developing countries. In addition there is an urgent need to address viral resistance with human combination vaccines,” says Sapna Jha, a lead research expert on vaccines from Technavio.

Technavio’s research analysts segment the global human combination vaccines market into the following regions:

  • Americas
  • EMEA
  • APAC

Human combination vaccines market in Americas

The human combination vaccines market in the Americas dominated the global market with a 46% share in 2016. The market is growing due to strict regulatory norms that recommend proper vaccination of infants born in the region. The continuous efforts by vendors and national organizations to promote the use of human combination vaccines will further drive the market growth in the Americas.

For instance, Merck, a large player engaged in the development and commercialization of therapeutics and vaccines, announced the launch of ILÚM Health Solutions in February 2016. ILÚM is an organization that provides disease management tools and services to patients with infectious diseases such as sepsis and pneumonia, thereby significantly improving the treatment outcomes.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

Human combination vaccines market in EMEA

In 2016, the human combination vaccines market in EMEA followed the Americas with a market share of around 36%. This market is expected to grow at a moderate rate during the forecast period due to rising awareness and established healthcare infrastructure in Europe.

Continuous efforts by vendors for the development of newer human combination vaccines will provide vast coverage against various diseases. For instance, in February 2016, Sanofi obtained a European license for its PR5i hexavalent combination vaccine, which will be marketed as Vaxelis. This vaccine will provide immunization coverage against diphtheria, tetanus, pertussis, polio, HIB, and Hep B infections.

Human combination vaccines market in APAC

“The human combination vaccines market in APAC had the lowest market share of more than 18% in 2016. However, the market is expected to grow at a higher rate than other regions during the forecast period due to increasing pediatric population and rising awareness about vaccinations,” says Sapna.

Increase in partnerships between vendors to develop innovative vaccines will also drive the market growth. For instance, in March 2012, GlaxoSmithKline signed an agreement with Daiichi Sankyo to create the number one vaccines company in Japan.

The top vendors in the global human combination vaccines market as highlighted in this market research analysis are:

  • GlaxoSmithKline
  • Merck
  • Sanofi

Browse Related Reports:

Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as they’re published in addition to all 6,000+ existing reports covering segments like patient monitoring devices, medical imaging, and oncology. This subscription nets you thousands in savings, while staying connected to Technavio’s constant transforming research library, helping you make informed business decisions more efficiently.

About Technavio

Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.

Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com

Release Summary

The global human combination vaccines market is expected to grow at a CAGR of close to 9% during the forecast period, 2017-2021.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com